Effect of Single and Double Administration of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Following Focal Cerebral Ischemia in Rats

Stem cell therapies are administered during the acute phase of stroke to preserve the penumbral tissues from ischemic injury. However, the effect of repeated cell therapy during the acute phase remains unclear. In this study, we investigated and compared the functional outcome of single (two days post-injury) and repeated (two and nine days post-injury) treatment with human umbilical cord derived mesenchymal stem cells (hUCB-MSCs) after middle cerebral artery occlusion (MCAO). The rotarod and limb placement tests were utilized to investigate functional outcomes, while infarct volume and tissue damage were measured by immunofluorescent staining for neovascularization, neurogenesis, apoptosis, and inflammation in the penumbral zones. We observed notable motor dysfunction and a significant decrease in infarcted brain volume, as well as increases in neurons and vessels in both single and repeated hUCB-MSC treatments compared to the control group. Interestingly, repeated administration of hUCB-MSCs was not found to elicit additional or synergistic improvements over monotherapy. This study suggests that a clearer understanding of the therapeutic window after stroke will facilitate the development of more efficient treatment protocols in the clinical application of stem cell therapy.

[1]  Seung Leal Paek,et al.  Human umbilical cord blood‐derived mesenchymal stem cells improve functional recovery through thrombospondin1, pantraxin3, and vascular endothelial growth factor in the ischemic rat brain , 2015, Journal of neuroscience research.

[2]  Seok-Goo Cho,et al.  New Strategies for Overcoming Limitations of Mesenchymal Stem Cell-Based Immune Modulation , 2015, International journal of stem cells.

[3]  M. Chopp,et al.  Efficacy of Single and Multiple Injections of Human Umbilical Tissue-Derived Cells following Experimental Stroke in Rats , 2013, PloS one.

[4]  J. Middeldorp,et al.  GFAPδ Expression in Glia of the Developmental and Adolescent Mouse Brain , 2012, PloS one.

[5]  W. van't Hof,et al.  Application of MultiStem® Allogeneic Cells for Immunomodulatory Therapy: Clinical Progress and Pre-Clinical Challenges in Prophylaxis for Graft Versus Host Disease , 2012, Front. Immun..

[6]  P. simon-Assmann,et al.  Role of laminins in physiological and pathological angiogenesis. , 2011, The International journal of developmental biology.

[7]  A. Kavelaars,et al.  Repeated Mesenchymal Stem Cell Treatment after Neonatal Hypoxia–Ischemia Has Distinct Effects on Formation and Maturation of New Neurons and Oligodendrocytes Leading to Restoration of Damage, Corticospinal Motor Tract Activity, and Sensorimotor Function , 2010, The Journal of Neuroscience.

[8]  O. Bang,et al.  A Long‐Term Follow‐Up Study of Intravenous Autologous Mesenchymal Stem Cell Transplantation in Patients With Ischemic Stroke , 2010, Stem cells.

[9]  S. Kim,et al.  GD2 expression is closely associated with neuronal differentiation of human umbilical cord blood-derived mesenchymal stem cells , 2010, Cellular and Molecular Life Sciences.

[10]  A. Kavelaars,et al.  Regeneration of the ischemic brain by engineered stem cells: Fuelling endogenous repair processes , 2009, Brain Research Reviews.

[11]  M. Chopp,et al.  Neurorestorative therapies for stroke: underlying mechanisms and translation to the clinic , 2009, The Lancet Neurology.

[12]  K. Houkin,et al.  Optimization of a therapeutic protocol for intravenous injection of human mesenchymal stem cells after cerebral ischemia in adult rats , 2008, Brain Research.

[13]  A. P. Robinson,et al.  Stem/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune responses , 2008, Proceedings of the National Academy of Sciences.

[14]  S. Paek,et al.  Endogenous neurogenesis and neovascularization in the neocortex of the rat after focal cerebral ischemia , 2008, Journal of neuroscience research.

[15]  R. Henning,et al.  Human Cord Blood Cells and Myocardial Infarction: Effect of Dose and Route of Administration on Infarct Size , 2007, Cell transplantation.

[16]  K. Houkin,et al.  Intravenous administration of glial cell line‐derived neurotrophic factor gene‐modified human mesenchymal stem cells protects against injury in a cerebral ischemia model in the adult rat , 2006, Journal of neuroscience research.

[17]  K. Houkin,et al.  Intravenous infusion of immortalized human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat , 2006, Experimental Neurology.

[18]  D. Steindler,et al.  Mesenchymal Stem Cells Spontaneously Express Neural Proteins in Culture and Are Neurogenic after Transplantation , 2006, Stem cells.

[19]  P. Sanberg,et al.  Timing of Cord Blood Treatment after Experimental Stroke Determines Therapeutic Efficacy , 2006, Cell transplantation.

[20]  K. Houkin,et al.  I.v. infusion of brain-derived neurotrophic factor gene-modified human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat , 2005, Neuroscience.

[21]  Yi Li,et al.  Gliosis and brain remodeling after treatment of stroke in rats with marrow stromal cells , 2005, Glia.

[22]  F. Tortella,et al.  Microarray analysis of acute and delayed gene expression profile in rats after focal ischemic brain injury and reperfusion , 2004, Journal of neuroscience research.

[23]  K. Houkin,et al.  A therapeutic window for intravenous administration of autologous bone marrow after cerebral ischemia in adult rats , 2004, Brain Research.

[24]  M. Chopp,et al.  Intravenous bone marrow stromal cell therapy reduces apoptosis and promotes endogenous cell proliferation after stroke in female rat , 2003, Journal of neuroscience research.

[25]  M. Chopp,et al.  Human marrow stromal cell therapy for stroke in rat: Neurotrophins and functional recovery , 2002, Neurology.

[26]  M. Chopp,et al.  Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats , 2001, Journal of the Neurological Sciences.

[27]  M. Chopp,et al.  Therapeutic Benefit of Intravenous Administration of Bone Marrow Stromal Cells After Cerebral Ischemia in Rats , 2001, Stroke.

[28]  D. Dawson,et al.  Targeting of marrow-derived astrocytes to the ischemic brain. , 1999, Neuroreport.

[29]  W. Pardridge,et al.  Neuroprotection with noninvasive neurotrophin delivery to the brain. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[30]  P. Cuevas Therapeutic prospects for fibroblast growth factor treatment of brain ischemia. , 1997, Neurological research.

[31]  B. Pike,et al.  The rotarod test: an evaluation of its effectiveness in assessing motor deficits following traumatic brain injury. , 1994, Journal of neurotrauma.

[32]  M. Borgers,et al.  Photochemical stroke model: flunarizine prevents sensorimotor deficits after neocortical infarcts in rats. , 1989, Stroke.